SCHEMBL3533912

SCHEMBL3533912

CN1CCN(c2ccc3nc(-c4n[nH]c5c(NC(=O)c6ccc(F)cc6F)cccc45)[nH]c3c2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 15/20 0.56
FLT1 P17948 6/20 0.56
FLT3 P36888 4/20 0.51
KDR P35968 11/20 0.49
PDGFRB P09619 8/20 0.49
PDPK1 O15530 2/20 0.44
PDGFRA P16234 2/20 0.44
FGFR2 P21802 2/20 0.44
FGFR4 P22455 2/20 0.44
FGFR3 P22607 2/20 0.44
CDK4 P11802 2/20 0.44
PLK4 O00444 1/20 0.44
STK25 O00506 1/20 0.44
CIT O14578 1/20 0.44
RIOK3 O14730 1/20 0.44
CHEK1 O14757 1/20 0.44
GAK O14976 1/20 0.44
CHUK O15111 1/20 0.44
MUSK O15146 1/20 0.44
EPHB6 O15197 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3539925 0.89 PDPK1 (0.57) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3531929 0.88 FGFR1 (0.64) FGFR1FLT1KDRABL1BCR
SCHEMBL3537060 0.87 FGFR1 (0.58) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3532687 0.86 FGFR1 (0.63) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3541056 0.86 FGFR1 (0.65) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3539309 0.85 FLT3 (0.60) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3540307 0.85 FGFR1 (0.57) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3540105 0.84 FGFR1 (0.61) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3535285 0.79 FGFR1 (0.65) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3536048 0.79 PDPK1 (0.38) FGFR1FLT1FLT3KDRPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885FLT3 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.